Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B

Table 1 Baseline characteristics of the patients

Patient	Sex	Age(yr)	Liverbiopsy	Complica-tions	HBV DNA(pg/mL )1	LAM3(wk)	YMDD
1	F	77	Cirrhosis	HCC	8	96	M204I
2	M	40	CAH Ishak 9;2		2	156	M204V
3	M	63	Cirrhosis		Undetectable2	188	M204V
4	F	68	Cirrhosis	F2 esoph varices	1600	44	M204I
5	M	55	Cirrhosis		Undetectable2	104	M204V, L180M
6	F	58	Cirrhosis		450	88	WT
7	M	68	Cirrhosis	F2 esoph varices	64	76	WT
8	M	57	CAH Ishak 7; 4		162	116	WT
9	M	65	Cirrhosis		78	88	WT
10	M	58	Cirrhosis		0.2	52	WT
11	F	75	Cirrhosis		3.100	116	WT

¹Basal HBV DNA (Digene Capture 2 Assay, sensitivity 0.2 pg/mL, equal to 105 copies/mL) before starting lamivudine;

²Sample taken after ALT flare;

³Duration of lamivudine treatment before starting tenofovir; esoph: esophageal.

Table 2 Results of treatment with tenofovir disoproxil fumarate (TDF) in the individual patients

Patient(YMDD/WT)	BasalHBVDNA1(cp/mL)	Durationoftreatmentwith TDF(wk)	HBVDNA(end ofTDF)( cp/mL)	Drugsubstituted for TDF	HBV DNAaftersubstitutionof TDF
1 (YMDD)	1000-2000	96	< 1000	ADV	130.000 cp/mL
2 (YMDD)	4.8 × 106	144	< 1000	ADV	No viral
					rebound
3 (YMDD)	1000-2000	56	< 1000	LAM	No viral
					rebound
4 (YMDD)	1000-2000	80	< 10002	ADV + LAM	No viral
					rebound
5 (YMDD)	1000-2000	60	< 1000	ADV	No viral
					rebound
6 WT	< 1000	108	< 1000	ADV	No viral
					rebound
7 WT	< 1000	76	< 1000	ADV	21 000 cp/mL
8 WT	< 1000	88	< 1000	ADV	2700 cp/mL
9 WT	< 1000	116	< 1000	ADV	No viral
					rebound
10 WT	< 1000	52	< 1000	LAM added to	No viral
				TDF	rebound
11 WT	< 1000	24	< 1000	LAM	No viral
					rebound

¹At the end of lamivudine treatment and before starting TDF;

²After 8 mo of TDF, HBVDNA was unchanged but YMDD disappeared. Lamivudine was then added to TDF with prompt decrease of DNA below 1000 cp/mL.